Open an account

IGC Pharma

IGC · NYSE American

$0.245+$0.003 (+1.24%)TodayMarket closed ·
Prev close $0.242

About IGC

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The firm integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. The company is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.

Employees
70
Headquarters
Potomac, Maryland
Listed
Apr 13, 2006
Sector
Health Care
Industry
Pharmaceuticals
Website
igcpharma.com

IGC key statistics

Market cap
25.33M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
641.67K
Volume
447.57K
Open price
$0.2409
High today
$0.2547
Low today
$0.2401
52 Week high
$0.4508
52 Week low
$0.235

IGC Pharma (IGC) at a glance

IGC Pharma (IGC) last traded at $0.245, with a market cap of 25.33M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2401 and $0.2547. The current price is 2.0% above the day's low and 3.8% below its high.

Volume so far is 447.57K shares, below the average of 641.67K shares a day.

Over the past year IGC Pharma has ranged from $0.235 to $0.4508, and now sits 5% of the way up that range.

IGC Pharma met or beat analyst EPS estimates in 4 of the last 6 quarters. In Q1 FY26 it reported -$0.02 per share against an estimate of -$0.0233.

The average analyst price target is $4.08, 1565.3% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $4.08
Low
$3.03
Now
$0.245
High
$5.25

IGC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 6 quarters, by 21.9% on average.

  1. Q4 FY24: reported -$0.40 per share against an estimate of -$0.0404
  2. Q1 FY25: reported -$0.03 per share against an estimate of -$0.0262
  3. Q2 FY25: reported -$0.02 per share against an estimate of -$0.0262
  4. Q3 FY25: reported -$0.024 per share against an estimate of -$0.0262
  5. Q4 FY25: reported -$0.01 per share against an estimate of -$0.0171
  6. Q1 FY26: reported -$0.02 per share against an estimate of -$0.0233

IGC news

  • 'Trump Reclassifies State-Licensed Medical Marijuana As A Less-Dangerous Drug In A Historic Shift' - AP News

  • Avi Kapoor

    Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

  • 'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News

  • UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Rishabh Mishra

    US Stocks Likely To Open Higher, Continuing Record-Setting Advances: June Has Never Seen An All-Time High Since 1950, Highlights Expert

  • Nina Zdinjak

    Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial

  • Press releaseBusiness Wire

    IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Similar companies

Companies in the same industry as IGC Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.